Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Crister Ceberg

Professor

Default user image.

Performance of sulfhydryl boron hydride in patients with grade III and IV astrocytoma: a basis for boron neutron capture therapy

Författare

  • Crister Ceberg
  • Anders Persson
  • Arne Brun
  • René Huiskamp
  • Ann-Sofie Fyhr
  • Bertil R Persson
  • Leif Salford

Summary, in English

This study investigated the rationale of boron neutron capture therapy (BNCT) for the treatment of Grade III and IV astrocytoma. The European Community joint research program on BNCT plans to use sulfhydryl boron hydride (BSH) in clinical trials. The work presented here, examines the performance of BSH in eight patients with Grade III and IV astrocytoma using a measurement technique which precisely correlates the boron uptake with the histology of the tumor and the peritumoral brain. Astrocytomas are exceptionally heterogeneous and spread migrating tumor cells into the surrounding brain. The patients were infused with 50 mg BSH per kilogram of body weight at 12, 18, 24 or 48 hours before surgery. At the time of operation, specimens were obtained of the tumor, skin, muscle, dura, blood, urine, and, when surgically possible, the brain adjacent to tumor. In three patients the intracellular boron distribution was investigated by subcellular fractionation. The blood clearance was biphasic with half-lives of 0.6 and 8.2 hours. After 3 days, approximately 70% of the dose injected was excreted in the urine. The maximum boron concentration in the tumor was 20 ppm, 12 hours after the infusion. The tumor-to-blood ratios ranged between 0.2 and 1.4, with the highest values after 18 to 24 hours. In the brain specimens the boron concentration never exceeded 1 ppm. This work confirms a selective uptake of boron in the tumor compared to the surrounding brain and that boron, to some extent, is incorporated in the tumor cells.

Avdelning/ar

  • Medicinsk strålningsfysik, Lund
  • Tumörmikromiljö
  • Neurokirurgi

Publiceringsår

1995

Språk

Engelska

Sidor

79-85

Publikation/Tidskrift/Serie

Journal of Neurosurgery

Volym

83

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

American Association of Neurosurgeons

Ämne

  • Neurology
  • Surgery

Nyckelord

  • biodistribution
  • astrocytoma
  • sulfhydryl boron hydride
  • boron neutron capture therapy

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0022-3085